Cargando…
Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials
BACKGROUND: Blue Cone Monochromacy (BCM) is an X-linked retinopathy caused by mutations in the OPN1LW / OPN1MW gene cluster, encoding long (L)- and middle (M)-wavelength sensitive cone opsins. Recent evidence shows sufficient structural integrity of cone photoreceptors in BCM to warrant consideratio...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409040/ https://www.ncbi.nlm.nih.gov/pubmed/25909963 http://dx.doi.org/10.1371/journal.pone.0125700 |
_version_ | 1782368141486063616 |
---|---|
author | Luo, Xunda Cideciyan, Artur V. Iannaccone, Alessandro Roman, Alejandro J. Ditta, Lauren C. Jennings, Barbara J. Yatsenko, Svetlana A. Sheplock, Rebecca Sumaroka, Alexander Swider, Malgorzata Schwartz, Sharon B. Wissinger, Bernd Kohl, Susanne Jacobson, Samuel G. |
author_facet | Luo, Xunda Cideciyan, Artur V. Iannaccone, Alessandro Roman, Alejandro J. Ditta, Lauren C. Jennings, Barbara J. Yatsenko, Svetlana A. Sheplock, Rebecca Sumaroka, Alexander Swider, Malgorzata Schwartz, Sharon B. Wissinger, Bernd Kohl, Susanne Jacobson, Samuel G. |
author_sort | Luo, Xunda |
collection | PubMed |
description | BACKGROUND: Blue Cone Monochromacy (BCM) is an X-linked retinopathy caused by mutations in the OPN1LW / OPN1MW gene cluster, encoding long (L)- and middle (M)-wavelength sensitive cone opsins. Recent evidence shows sufficient structural integrity of cone photoreceptors in BCM to warrant consideration of a gene therapy approach to the disease. In the present study, the vision in BCM is examined, specifically seeking clinically-feasible outcomes for a future clinical trial. METHODS: BCM patients (n = 25, ages 5–72) were studied with kinetic and static chromatic perimetry, full-field sensitivity testing, and eye movement recordings. Vision at the fovea and parafovea was probed with chromatic microperimetry. RESULTS: Kinetic fields with a Goldmann size V target were generally full. Short-wavelength (S-) sensitive cone function was normal or near normal in most patients. Light-adapted perimetry results on conventional background lights were abnormally reduced; 600-nm stimuli were seen by rods whereas white stimuli were seen by both rods and S-cones. Under dark-adapted conditions, 500-nm stimuli were seen by rods in both BCM and normals. Spectral sensitivity functions in the superior retina showed retained rod and S-cone functions in BCM under dark-adapted and light-adapted conditions. In the fovea, normal subjects showed L/M-cone mediation using a 650-nm stimulus under dark-adapted conditions, whereas BCM patients had reduced sensitivity driven by rod vision. Full-field red stimuli on bright blue backgrounds were seen by L/M-cones in normal subjects whereas BCM patients had abnormally reduced and rod-mediated sensitivities. Fixation location could vary from fovea to parafovea. Chromatic microperimetry demonstrated a large loss of sensitivity to red stimuli presented on a cyan adapting background at the anatomical fovea and surrounding parafovea. CONCLUSIONS: BCM rods continue to signal vision under conditions normally associated with daylight vision. Localized and retina-wide outcome measures were examined to evaluate possible improvement of L/M-cone-based vision in a clinical trial. |
format | Online Article Text |
id | pubmed-4409040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-44090402015-05-12 Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials Luo, Xunda Cideciyan, Artur V. Iannaccone, Alessandro Roman, Alejandro J. Ditta, Lauren C. Jennings, Barbara J. Yatsenko, Svetlana A. Sheplock, Rebecca Sumaroka, Alexander Swider, Malgorzata Schwartz, Sharon B. Wissinger, Bernd Kohl, Susanne Jacobson, Samuel G. PLoS One Research Article BACKGROUND: Blue Cone Monochromacy (BCM) is an X-linked retinopathy caused by mutations in the OPN1LW / OPN1MW gene cluster, encoding long (L)- and middle (M)-wavelength sensitive cone opsins. Recent evidence shows sufficient structural integrity of cone photoreceptors in BCM to warrant consideration of a gene therapy approach to the disease. In the present study, the vision in BCM is examined, specifically seeking clinically-feasible outcomes for a future clinical trial. METHODS: BCM patients (n = 25, ages 5–72) were studied with kinetic and static chromatic perimetry, full-field sensitivity testing, and eye movement recordings. Vision at the fovea and parafovea was probed with chromatic microperimetry. RESULTS: Kinetic fields with a Goldmann size V target were generally full. Short-wavelength (S-) sensitive cone function was normal or near normal in most patients. Light-adapted perimetry results on conventional background lights were abnormally reduced; 600-nm stimuli were seen by rods whereas white stimuli were seen by both rods and S-cones. Under dark-adapted conditions, 500-nm stimuli were seen by rods in both BCM and normals. Spectral sensitivity functions in the superior retina showed retained rod and S-cone functions in BCM under dark-adapted and light-adapted conditions. In the fovea, normal subjects showed L/M-cone mediation using a 650-nm stimulus under dark-adapted conditions, whereas BCM patients had reduced sensitivity driven by rod vision. Full-field red stimuli on bright blue backgrounds were seen by L/M-cones in normal subjects whereas BCM patients had abnormally reduced and rod-mediated sensitivities. Fixation location could vary from fovea to parafovea. Chromatic microperimetry demonstrated a large loss of sensitivity to red stimuli presented on a cyan adapting background at the anatomical fovea and surrounding parafovea. CONCLUSIONS: BCM rods continue to signal vision under conditions normally associated with daylight vision. Localized and retina-wide outcome measures were examined to evaluate possible improvement of L/M-cone-based vision in a clinical trial. Public Library of Science 2015-04-24 /pmc/articles/PMC4409040/ /pubmed/25909963 http://dx.doi.org/10.1371/journal.pone.0125700 Text en © 2015 Luo et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Luo, Xunda Cideciyan, Artur V. Iannaccone, Alessandro Roman, Alejandro J. Ditta, Lauren C. Jennings, Barbara J. Yatsenko, Svetlana A. Sheplock, Rebecca Sumaroka, Alexander Swider, Malgorzata Schwartz, Sharon B. Wissinger, Bernd Kohl, Susanne Jacobson, Samuel G. Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials |
title | Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials |
title_full | Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials |
title_fullStr | Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials |
title_full_unstemmed | Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials |
title_short | Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials |
title_sort | blue cone monochromacy: visual function and efficacy outcome measures for clinical trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409040/ https://www.ncbi.nlm.nih.gov/pubmed/25909963 http://dx.doi.org/10.1371/journal.pone.0125700 |
work_keys_str_mv | AT luoxunda blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT cideciyanarturv blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT iannacconealessandro blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT romanalejandroj blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT dittalaurenc blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT jenningsbarbaraj blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT yatsenkosvetlanaa blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT sheplockrebecca blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT sumarokaalexander blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT swidermalgorzata blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT schwartzsharonb blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT wissingerbernd blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT kohlsusanne blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials AT jacobsonsamuelg blueconemonochromacyvisualfunctionandefficacyoutcomemeasuresforclinicaltrials |